US Patent

US12409184 — Iloprost compositions and formulations thereof

Formulation · Assigned to BTG International Inc · Expires 2041-08-06 · 15y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and formulations of iloprost for intravenous or subcutaneous administration to treat systemic sclerosis with symptomatic Raynaud's Phenomenon.

USPTO Abstract

The present disclosure generally relates to treatment of systemic sclerosis with symptomatic Raynaud's Phenomenon by intravenous or subcutaneous administration of iloprost or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number: US12409184
Jurisdiction: US
Classification: Formulation
Expires: 2041-08-06
Drug substance claim: No
Drug product claim: Yes
Assignee: BTG International Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.